Christiaan de Bruin

Christiaan de Bruin

Auto-generated profile, based on publicly available information

Christiaan de Bruin

Division of Endocrinology, Department of Pediatrics, Leiden University Medical Center, Willem-Alexander Children’s Hospital , Leiden

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2020 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
JWJan M. Wit
Jan M. Wit
MBMartin Bidlingmaier
Martin Bidlingmaier
CBChristiaan de Bruin
Christiaan de Bruin
WOWilma Oostdijk
Wilma Oostdijk
The serum IGF-I concentration is commonly used as a screening tool for growth hormone deficiency (GHD), but there is no consensus on the cut-off limit of IGF-I standard deviation score (SDS) to perform GH stimulation tests for confirmation or exclusion of GHD. We argue that the cut-off limit is dependent on the clinical pre-test likelihood of GHD and propose a diagnostic strategy in which the cut-off limit varies between none to -2 SDS.

15 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
AMAvinaash Vickram Maharaj
Avinaash Vickram Maharaj
ECEmily Cottrell
Emily Cottrell
TTThatchawan Thanasupawat
Thatchawan Thanasupawat
SJSjoerd D. Joustra
Sjoerd D. Joustra
Barbara Triggs-RaineBarbara Triggs-Raine
Barbara Triggs-Raine
HSHelen L. Storr
Helen L. Storr
Silver-Russell syndrome (SRS) is a heterogeneous disorder characterized by intrauterine and postnatal growth retardation. HMGA2 variants are a rare cause of SRS and its functional role in human linear growth is unclear. Patients with suspected SRS negative for 11p15LOM/mUPD7 underwent whole-exome and/or targeted-genome sequencing. Mutant HMGA2 protein expression and nuclear localization were assessed. Two Hmga2 -knockin mouse models were generated. Five clinical SRS patients harbored HMGA2 variants with differing functional impacts: 2 stop-gain nonsense variants (c.49G>T, c.52C>T), c.166A>G missense variant, and 2 frameshift variants (c.144delC, c.145delA) leading to an identical, extended-length protein. Phenotypic features were highly variable. Nuclear localization was reduced/absent for all variants except c.166A>G. Homozygous knockin mice recapitulating the c.166A>G variant ( Hmga2 K56E ) exhibited a growth-restricted phenotype. An Hmga2 Ter76 -knockin mouse model lacked detectable full-length Hmga2 protein, similarly to patient 3 and 5 variants. These mice were infertile, with a pygmy phenotype. We report a heterogeneous group of individuals with SRS harboring variants in HMGA2 and describe the first Hmga2 missense knockin mouse model ( Hmga2 K56E ) to our knowledge causing a growth-restricted phenotype. In patients with clinical features of SRS but negative genetic screening, HMGA2 should be included in next-generation sequencing testing approaches.

15 November 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
JVJoeri Vliegenthart
Joeri Vliegenthart
JWJan M Wit
Jan M Wit
BBBoudewijn Bakker
Boudewijn Bakker
ABAnnemieke M Boot
Annemieke M Boot
CBChristiaan de Bruin
Christiaan de Bruin
DKDanielle C M van der Kaay
Danielle C M van der Kaay
Context: In children with idiopathic isolated growth hormone deficiency (IIGHD), GH secretion often normalizes by near adult height (NAH). Whether recombinant human GH (rhGH) treatment can be safely discontinued earlier remains unclear. Objective: This work aimed to investigate if withdrawing rhGH treatment from mid-puberty onward had no negative effect on attained NAH in adolescents who, after retesting, were no longer GH deficient. Methods: A prospective multicenter patient preference study was conducted at pediatric endocrinology departments in multiple centers (2017-2024) with follow-up until NAH (SEENEZ GH Study). Participants included 127 adolescents (95 male, 75%) with childhood IIGHD (GH peak 1.7-10 µg/L) who tested GH sufficient (GH peak >6.7 µg/L) at mid-puberty. Forty-four continued rhGH (GHcont), 83 discontinued (GHstop). A total of 99% of patients completed the study. Intervention included rhGH treatment continuation vs discontinuation from mid-puberty until NAH. The primary outcome measure was NAH-SDS minus target height (TH)-SDS. The secondary outcome was NAH-SDS, total pubertal growth (TPG), and predicted vs attained height gain. Results: Mean (SD) NAH-SDS minus TH-SDS was −0.17 (0.60) in the GHcont and −0.18 (0.62) in the GHstop group (P = .96). Mean NAH-SDS was −0.91 (0.76) (GHcont) vs −0.78 (0.76) (GHstop) (P = .35). Mean (SD) TPG (from start of puberty) in males was 27.5 cm (7.0; GHcont) vs 25.9 cm (6.2; GHstop) (P = .25) and in females 20.5 cm (5.7; GHcont) vs 20.9 cm (7.6; GHstop) (P = .90). Predicted vs attained height gain based on the prediction model did not differ between groups. Conclusions: In adolescents with transient IIGHD, rhGH treatment can be stopped at mid-puberty. These findings support reducing rhGH treatment duration, lowering patient burden and health-care costs.

4 March 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
DZDaniël Zwerus
Daniël Zwerus
ASAnnemarie A Verrijn Stuart
Annemarie A Verrijn Stuart
HSHanneke M van Santen
Hanneke M van Santen
GVGerlof D. Valk
Gerlof D. Valk
CBChristiaan de Bruin
Christiaan de Bruin
RLRachel S van Leeuwaarde
Rachel S van Leeuwaarde
Context: Multiple Endocrine Neoplasia (MEN) syndromes are rare autosomal dominant hereditary tumor predisposition syndromes affecting multiple family members. Carriers undergo health surveillance from early childhood onwards. Carriership or surveillance may influence Health-Related Quality of Life (HRQoL) for patients or their families. Objective: To evaluate HRQoL in children and adolescents with genetically confirmed MEN1, MEN2A, and MEN2B, and to compare outcomes with their siblings without MEN and healthy Dutch norms. Secondary aims were to explore associations between HRQoL and clinical characteristics. Methods: This nationwide cross-sectional study included 77 children with MEN (5-18 years) and 26 siblings (8-29 years). The Pediatric Quality of Life Inventory (PedsQL) was used to assess HRQoL, with children completing self-report questionnaires and parents providing proxy reports for their children with MEN. Sociodemographic and clinical data were obtained from medical records. Results: Children with MEN1 and MEN2A reported HRQoL comparable to siblings and healthy Dutch norms. Only children with MEN2B showed significantly lower physical HRQoL. No gender or age effects were observed. Parent-proxy scores were significantly higher than child self-reports on all domains, except for emotional functioning. Children with MEN1 and MEN2B having clinical MEN-related manifestations had significantly lower physical, social, and school functioning scores than those without clinical manifestations. Conclusion: Overall, children with MEN reported HRQoL comparable to siblings and age-matched Dutch norms, except for reduced physical functioning in MEN2B. Clinical manifestations negatively affected physical, social, and school functioning, suggesting that children with the onset of disease may benefit from closer monitoring and targeted psychosocial support.

14 January 2026 in The Journal of Steroid Biochemistry and Molecular Biology
Verified
Journal Article
Open access
PAPhilipp Augsburger
Philipp Augsburger
TTTherina Du Toit
Therina Du Toit
EAEmre Murat Altinkiliç
Emre Murat Altinkiliç
SHSabine Hannema
Sabine Hannema
CBChristiaan de Bruin
Christiaan de Bruin
CFChrista Fluck
Christa Fluck
Thyroid hormones (THs) are critical regulators of human development, cellular differentiation, and metabolism. While their systemic effects are well established, their role in adrenal androgen production remains poorly defined. Moreover, potential feedback regulation of the hypothalamic-pituitary-thyroid (HPT) axis by adrenal androgens has not been thoroughly investigated. This study aimed to clarify the regulatory effects of THs on adrenal androgens and to investigate potential feedback mechanisms in patients with congenital adrenal hyperplasia (CAH). In an in-vitro experiment, treatment with 3,3',5-triiodo-L-thyronine (T3) on adrenocortical carcinoma H295R cells significantly reduced dehydroepiandrosterone (DHEA) and DHEA-sulfate production while modestly increasing testosterone (T) and androstenedione (A4). These changes were associated with an increase in expression of HSD3B2 and AKR1C3, and a decrease of CYP17A1. Transcriptomic analysis additionally revealed enrichment of pathways related to steroidogenesis and adrenal development through T3 treatment. In the clinical part of the study, hormone levels in pediatric CAH patients were analyzed. Serum free thyroxine (fT4) and thyroid-stimulating hormone (TSH) showed weak negative correlations with the adrenal androgens DHEA and A4. However, no differences in fT4 or TSH concentrations were observed between well-controlled and hyperandrogenic patients, suggesting a lack of feedback regulation by adrenal androgens on the HPT axis. In conclusion, these findings suggest that THs regulate adrenal androgen production by modulating the activity of key steroidogenic enzymes. This relationship appears to be predominantly unidirectional, with THs influencing adrenal steroidogenesis but adrenal androgens not altering HPT axis function.

1 September 2019 in Journal of Clinical Research in Pediatric Endocrinology
Verified
Journal Article
Open access
POPaula Ocaranza
Paula Ocaranza
MLMonique Losekoot
Monique Losekoot
MWMarie J. E. Walenkamp
Marie J. E. Walenkamp
CBChristiaan De Bruin
Christiaan De Bruin
JWJan M. Wit
Jan M. Wit
VMVeronica Mericq
Veronica Mericq
Objective: Insulin like growth factors-I (IGF-1) is essential for normal in utero and postnatal human growth. It mediates its effects through the IGF-1 receptor (IGFIR), a widely expressed cell surface tyrosine kinase receptor. The aim of the study was to analyze pre- and post-natal growth, clinical features and laboratory findings in a small for gestational age (SGA) girl in whom discordant postnatal growth persisted and her appropriate for gestational age (AGA) brother. Methods: A girl born with a low weight and length [-2.3 and -2.4 standard deviation (SD) score (SDS), respectively] but borderline low head circumference (-1.6 SD) presented with a height of -1.7 SDS, in contrast to a normal height twin brother (0.0 SDS). IGF-I resistance was suspected because of elevated serum IGF- I levels. Results: Sequencing revealed the presence of a previously described pathogenic heterozygous mutation (p.Glu1050Lys) in the SGA girl which was not present in the parents nor in the AGA twin brother. Conclusion: The pathogenic IGFIR mutation in this girl led to intrauterine growth retardation followed by partial postnatal catch-up growth. Height in mid-childhood was in the lower half of the reference range, but still 1.7 SD shorter than her twin brother.